UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Reactive arthritis

Author
David T Yu, MD
Section Editor
Joachim Sieper, MD
Deputy Editor
Paul L Romain, MD

INTRODUCTION

Reactive arthritis is conventionally defined as an arthritis that arises following an infection, although the pathogens cannot be cultured from the affected joints. It is generally regarded as a form of spondyloarthritis (SpA).

The definition, clinical features, approach to diagnosis and differential diagnosis, and management of reactive arthritis will be reviewed here. Mechanisms that may play a role in reactive arthritis and in other spondyloarthritides are discussed separately. (See "Mechanisms for the induction of rheumatic symptoms by gastrointestinal disease" and "Pathogenesis of spondyloarthritis".)

DEFINITION

The term “reactive arthritis” was introduced in 1969 as “an arthritis which developed soon after or during an infection elsewhere in the body, but in which the microorganisms cannot be recovered from the joint” [1]. The original definition did not specify the pathogens that were accepted as causes of reactive arthritis, and, in 1999, a panel of experts determined a specific list of gastrointestinal and urogenital pathogens that could be considered causative [2]. These included Chlamydia trachomatis, Yersinia, Salmonella, Shigella, and Campylobacter [2]. Escherichia coli, Clostridium difficile, and Chlamydia pneumoniae have since been added to the list [3-7].

Additional causative pathogens, alternative terms, and diagnostic and therapeutic strategies for reactive arthritis have subsequently been proposed [8]. However, none of the newer diagnostic or therapeutic approaches or alternate names has been adequately validated. Another problem is that many of the studies generating these approaches involved patients seen in rheumatology clinics or followed outbreaks of disease after exposure to a common pathogen; such patients are not likely to be representative of the affected patients in the general community. Thus, the definition of reactive arthritis is still evolving.

Two major clinical features that characterize reactive arthritis were identified [2]:

                                     

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Nov 2016. | This topic last updated: Thu Jul 21 00:00:00 GMT+00:00 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
References
Top
  1. Ahvonen P, Sievers K, Aho K. Arthritis associated with Yersinia enterocolitica infection. Acta Rheumatol Scand 1969; 15:232.
  2. Braun J, Kingsley G, van der Heijde D, Sieper J. On the difficulties of establishing a consensus on the definition of and diagnostic investigations for reactive arthritis. Results and discussion of a questionnaire prepared for the 4th International Workshop on Reactive Arthritis, Berlin, Germany, July 3-6, 1999. J Rheumatol 2000; 27:2185.
  3. Townes JM. Reactive arthritis after enteric infections in the United States: the problem of definition. Clin Infect Dis 2010; 50:247.
  4. Rohekar S, Pope J. Epidemiologic approaches to infection and immunity: the case of reactive arthritis. Curr Opin Rheumatol 2009; 21:386.
  5. Pope JE, Krizova A, Garg AX, et al. Campylobacter reactive arthritis: a systematic review. Semin Arthritis Rheum 2007; 37:48.
  6. Hannu T. Reactive arthritis. Best Pract Res Clin Rheumatol 2011; 25:347.
  7. Morris D, Inman RD. Reactive arthritis: developments and challenges in diagnosis and treatment. Curr Rheumatol Rep 2012; 14:390.
  8. Hannu T, Inman R, Granfors K, Leirisalo-Repo M. Reactive arthritis or post-infectious arthritis? Best Pract Res Clin Rheumatol 2006; 20:419.
  9. Panush RS, Wallace DJ, Dorff RE, Engleman EP. Retraction of the suggestion to use the term "Reiter's syndrome" sixty-five years later: the legacy of Reiter, a war criminal, should not be eponymic honor but rather condemnation. Arthritis Rheum 2007; 56:693.
  10. Keynan Y, Rimar D. Reactive arthritis--the appropriate name. Isr Med Assoc J 2008; 10:256.
  11. Townes JM, Deodhar AA, Laine ES, et al. Reactive arthritis following culture-confirmed infections with bacterial enteric pathogens in Minnesota and Oregon: a population-based study. Ann Rheum Dis 2008; 67:1689.
  12. Ajene AN, Fischer Walker CL, Black RE. Enteric pathogens and reactive arthritis: a systematic review of Campylobacter, salmonella and Shigella-associated reactive arthritis. J Health Popul Nutr 2013; 31:299.
  13. Horton DB, Strom BL, Putt ME, et al. Epidemiology of Clostridium difficile Infection-Associated Reactive Arthritis in Children: An Underdiagnosed, Potentially Morbid Condition. JAMA Pediatr 2016; 170:e160217.
  14. Leirisalo-Repo M, Sieper J. Reactive arthritis: epidemiology, clinical features, and treatment. In: Ankylosing spondylitis and the spondyloarthropathies, Weisman MH, van der Heijde D, Reveille JD (Eds), Mosby Elsevier, Philadelphia 2006. p.53.
  15. Collantes E, Zarco P, Muñoz E, et al. Disease pattern of spondyloarthropathies in Spain: description of the first national registry (REGISPONSER) extended report. Rheumatology (Oxford) 2007; 46:1309.
  16. Casals-Sánchez JL, García De Yébenes Prous MJ, Descalzo Gallego MÁ, et al. Characteristics of patients with spondyloarthritis followed in rheumatology units in Spain. emAR II study. Reumatol Clin 2012; 8:107.
  17. Carter JD, Rehman A, Guthrie JP, et al. Attack rate of Chlamydia-induced reactive arthritis and effect of the CCR5-Delta-32 mutation: a prospective analysis. J Rheumatol 2013; 40:1578.
  18. Kvien TK, Glennås A, Melby K, et al. Reactive arthritis: incidence, triggering agents and clinical presentation. J Rheumatol 1994; 21:115.
  19. Carter JD, Hudson AP. Reactive arthritis: clinical aspects and medical management. Rheum Dis Clin North Am 2009; 35:21.
  20. Carter JD, Inman RD. Chlamydia-induced reactive arthritis: hidden in plain sight? Best Pract Res Clin Rheumatol 2011; 25:359.
  21. Cuellar ML, Espinoza LR. Rheumatic manifestations of HIV-AIDS. Baillieres Best Pract Res Clin Rheumatol 2000; 14:579.
  22. Clark MR, Solinger AM, Hochberg MC. Human immunodeficiency virus infection is not associated with Reiter's syndrome. Data from three large cohort studies. Rheum Dis Clin North Am 1992; 18:267.
  23. Reveille JD, Conant MA, Duvic M. Human immunodeficiency virus-associated psoriasis, psoriatic arthritis, and Reiter's syndrome: a disease continuum? Arthritis Rheum 1990; 33:1574.
  24. Stein CM, Davis P. Arthritis associated with HIV infection in Zimbabwe. J Rheumatol 1996; 23:506.
  25. Leirisalo-Repo M. Reactive arthritis. Scand J Rheumatol 2005; 34:251.
  26. Zeidler H, Hudson AP. New insights into Chlamydia and arthritis. Promise of a cure? Ann Rheum Dis 2014; 73:637.
  27. Kvien TK, Gaston JS, Bardin T, et al. Three month treatment of reactive arthritis with azithromycin: a EULAR double blind, placebo controlled study. Ann Rheum Dis 2004; 63:1113.
  28. Ehrenfeld M. Spondyloarthropathies. Best Pract Res Clin Rheumatol 2012; 26:135.
  29. Leirisalo-Repo M, Helenius P, Hannu T, et al. Long-term prognosis of reactive salmonella arthritis. Ann Rheum Dis 1997; 56:516.
  30. Rothschild BM, Pingitore C, Eaton M. Dactylitis: implications for clinical practice. Semin Arthritis Rheum 1998; 28:41.
  31. Kovalev IuN, Il'in II. [Ophthalmological aspects of Reiter's disease]. Vestn Oftalmol 1990; 106:65.
  32. Kwiatkowska B, Filipowicz-Sosnowska A. Reactive arthritis. Pol Arch Med Wewn 2009; 119:60.
  33. Brown LE, Forfia P, Flynn JA. Aortic insufficiency in a patient with reactive arthritis: case report and review of the literature. HSS J 2011; 7:187.
  34. Kanakoudi-Tsakalidou F, Pardalos G, Pratsidou-Gertsi P, et al. Persistent or severe course of reactive arthritis following Salmonella enteritidis infection. A prospective study of 9 cases. Scand J Rheumatol 1998; 27:431.
  35. Cosh JA, Gerber N, Barritt DW, Jayson MI. Proceedings: Cardiac lesions in Reiter's syndrome and ankylosing spondylitis. Ann Rheum Dis 1975; 34:195.
  36. Stavropoulos PG, Soura E, Kanelleas A, et al. Reactive arthritis. J Eur Acad Dermatol Venereol 2015; 29:415.
  37. Rihl M, Klos A, Köhler L, Kuipers JG. Infection and musculoskeletal conditions: Reactive arthritis. Best Pract Res Clin Rheumatol 2006; 20:1119.
  38. Fendler C, Laitko S, Sörensen H, et al. Frequency of triggering bacteria in patients with reactive arthritis and undifferentiated oligoarthritis and the relative importance of the tests used for diagnosis. Ann Rheum Dis 2001; 60:337.
  39. Sieper J, Rudwaleit M, Braun J, van der Heijde D. Diagnosing reactive arthritis: role of clinical setting in the value of serologic and microbiologic assays. Arthritis Rheum 2002; 46:319.
  40. Aho K, Ahvonen P, Lassus A, et al. HL-A antigen 27 and reactive arthritis. Lancet 1973; 2:157.
  41. Leirisalo-Repo M, Hannu T, Mattila L. Microbial factors in spondyloarthropathies: insights from population studies. Curr Opin Rheumatol 2003; 15:408.
  42. Gerster JC, Vischer TL, Bennani A, Fallet GH. The painful heel. Comparative study in rheumatoid arthritis, ankylosing spondylitis, Reiter's syndrome, and generalized osteoarthrosis. Ann Rheum Dis 1977; 36:343.
  43. Ozgül A, Dede I, Taskaynatan MA, et al. Clinical presentations of chlamydial and non-chlamydial reactive arthritis. Rheumatol Int 2006; 26:879.
  44. Holland R, Barnsley L, Barnsley L. Viral arthritis. Aust Fam Physician 2013; 42:770.
  45. Bernini L, Manzini CU, Giuggioli D, et al. Reactive arthritis induced by intravesical BCG therapy for bladder cancer: our clinical experience and systematic review of the literature. Autoimmun Rev 2013; 12:1150.
  46. van der Helm-van Mil AH. Acute rheumatic fever and poststreptococcal reactive arthritis reconsidered. Curr Opin Rheumatol 2010; 22:437.
  47. Barber CE, Kim J, Inman RD, et al. Antibiotics for treatment of reactive arthritis: a systematic review and metaanalysis. J Rheumatol 2013; 40:916.
  48. Yli-Kerttula T, Luukkainen R, Yli-Kerttula U, et al. Effect of a three month course of ciprofloxacin on the late prognosis of reactive arthritis. Ann Rheum Dis 2003; 62:880.
  49. Lauhio A, Leirisalo-Repo M, Lähdevirta J, et al. Double-blind, placebo-controlled study of three-month treatment with lymecycline in reactive arthritis, with special reference to Chlamydia arthritis. Arthritis Rheum 1991; 34:6.
  50. Yli-Kerttula T, Luukkainen R, Yli-Kerttula U, et al. Effect of a three month course of ciprofloxacin on the outcome of reactive arthritis. Ann Rheum Dis 2000; 59:565.
  51. Laasila K, Laasonen L, Leirisalo-Repo M. Antibiotic treatment and long term prognosis of reactive arthritis. Ann Rheum Dis 2003; 62:655.
  52. Bardin T, Enel C, Cornelis F, et al. Antibiotic treatment of venereal disease and Reiter's syndrome in a Greenland population. Arthritis Rheum 1992; 35:190.
  53. Putschky N, Pott HG, Kuipers JG, et al. Comparing 10-day and 4-month doxycycline courses for treatment of Chlamydia trachomatis-reactive arthritis: a prospective, double-blind trial. Ann Rheum Dis 2006; 65:1521.
  54. Carter JD, Espinoza LR, Inman RD, et al. Combination antibiotics as a treatment for chronic Chlamydia-induced reactive arthritis: a double-blind, placebo-controlled, prospective trial. Arthritis Rheum 2010; 62:1298.
  55. Rudwaleit M, Braun J, Sieper J. Treatment of reactive arthritis: a practical guide. BioDrugs 2000; 13:21.
  56. Petersel DL, Sigal LH. Reactive arthritis. Infect Dis Clin North Am 2005; 19:863.
  57. Flores D, Marquez J, Garza M, Espinoza LR. Reactive arthritis: newer developments. Rheum Dis Clin North Am 2003; 29:37.
  58. Juvakoski T, Lassus A. A double-blind cross-over evaluation of ketoprofen and indomethacin in Reiter's disease. Scand J Rheumatol 1982; 11:106.
  59. Lassus A. A comparative pilot study of azapropazone and indomethacin in the treatment of psoriatic arthritis and Reiter's disease. Curr Med Res Opin 1976; 4:65.
  60. Clegg DO, Reda DJ, Weisman MH, et al. Comparison of sulfasalazine and placebo in the treatment of reactive arthritis (Reiter's syndrome). A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 1996; 39:2021.
  61. Flagg SD, Meador R, Hsia E, et al. Decreased pain and synovial inflammation after etanercept therapy in patients with reactive and undifferentiated arthritis: an open-label trial. Arthritis Rheum 2005; 53:613.
  62. Meyer A, Chatelus E, Wendling D, et al. Safety and efficacy of anti-tumor necrosis factor α therapy in ten patients with recent-onset refractory reactive arthritis. Arthritis Rheum 2011; 63:1274.
  63. Carlin EM, Keat AC, European Branch of the International Union against Sexually Transmitted Infection and the European Office of the World Health Organization. European guideline for the management of sexually acquired reactive arthritis. Int J STD AIDS 2001; 12 Suppl 3:94.
  64. Carter JD. Reactive Arthritis. In: Fitzpatrick's Dermatology in General Medicine, Eighth edition, Goldsmith LA, Katz SI, Gilchrest BA, et al. (Eds), McGraw Hill Medical, New York 2012. p.243.
  65. Leirisalo-Repo M, Repo H. Reactive arhtirits: clinical features and treatment. In: Rheumatology, 5th edition, Hochberg MC, Silman AJ, Smolen JS et al. (Eds), Elsevier/Mosby, Philadelphia, PA 2011. p.1113.
  66. Wu IB, Schwartz RA. Reiter's syndrome: the classic triad and more. J Am Acad Dermatol 2008; 59:113.
  67. Thiers BH. The use of topical calcipotriene/calcipotriol in conditions other than plaque-type psoriasis. J Am Acad Dermatol 1997; 37:S69.
  68. Louthrenoo W. Successful treatment of severe Reiter's syndrome associated with human immunodeficiency virus infection with etretinate. Report of 2 cases. J Rheumatol 1993; 20:1243.
  69. Benoldi D, Alinovi A, Bianchi G, Buticchi G. Reiter's disease: successful treatment of the skin manifestations with oral etretinate. Acta Derm Venereol 1984; 64:352.
  70. Leirisalo-Repo M, Suoranta H. Ten-year follow-up study of patients with Yersinia arthritis. Arthritis Rheum 1988; 31:533.
  71. Fox R, Calin A, Gerber RC, Gibson D. The chronicity of symptoms and disability in Reiter's syndrome. An analysis of 131 consecutive patients. Ann Intern Med 1979; 91:190.
  72. Hart HH, McGuigan LE, Gow PJ, Grigor RR. Reiter's syndrome: chronicity of symptoms and employment. Aust N Z J Med 1986; 16:452.